Using hypofractionated radiotherapy for thymic epithelial tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness and safety of hypofractionated radiotherapy compared to conventional radiotherapy in patients with thymic epithelial tumors following surgery. The study will assess whether hypofractionated radiotherapy can provide better treatment outcomes while reducing side effects and overall treatment time. Participants will receive either hypofractionated or conventional radiotherapy and will have regular follow-up visits every 12 weeks for monitoring. The goal is to determine if the shorter treatment course of hypofractionated radiotherapy can improve patient care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients must provide written informed consent.
2. 18 years old ≤ age \<75 years old.
3. Thymoma confirmed by pathology: type A, type AB, type B1, type B2, type B3. Thymic carcinoma. Patients with previous thymectomy were required to have complete surgical related data.
4. Masaoka⁃Koga ⁃ stage Ⅰ-Ⅲ
5. ECOG performance status 0-2.
6. Expected survival time \> 1 year.
7. Participants of childbearing age must agree to use effective contraception during the trial; In women of childbearing age, a serum or urine pregnancy test must be negative.
8. Patients who are not lactating.
9. Sufficient bone marrow reserve and good function of important organs.

Exclusion Criteria:

1. patients with prior thoracic radiotherapy;
2. diseases not suitable for radiotherapy, such as recent myocardial infarction, active congestive heart failure;
3. Uncontrolled infectious disease or other serious medical or mental illness that may interfere with care
4. Patients with other malignant tumors that are not under stable control;
5. Known history of mental illness, substance abuse, alcohol or drug abuse.
6. Other conditions deemed unsuitable for enrollment by the attending physician.

Where it's running

• Xiangya Hospital, Central South University
  Changsha, Hunan, China Recruiting

Study contacts

• Study coordinator: Rongrong Zhou, MD, PHD
• Email: zhourr@csu.edu.cn
• Phone: +8613875898127

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using AI to improve diagnosis and recurrence prediction in thymic tumors

  This study is testing if artificial intelligence can help doctors better diagnose thymic tumors and predict the chances of them coming back for patients with these rare cancers.

  Recruiting Erasmus Medical Center · Rotterdam, South Holland · NCT06301945

• Analysis and treatment options for thymic cancers

  This study is trying to find out how genetic changes in thymic cancers can help doctors create better, personalized treatments for patients.

  Recruiting Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT05667948

• Using PT-112 to treat thymoma and thymic carcinoma

  This study is testing a new treatment called PT-112 to see if it can help shrink tumors in patients with thymoma and thymic carcinoma who have already tried other chemotherapy.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05104736

• Postoperative Hypofractionated Radiotherapy for Stage II/III Thymic Epithelial Tumors

  This study tests whether giving a shorter course of higher-dose radiotherapy after complete tumor removal is safe for adults with Stage II/III thymic epithelial tumors.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07691619

• Tislelizumab plus anlotinib as a second-line treatment for thymoma and thymic carcinoma

  This trial will test whether combining tislelizumab with anlotinib is safe and can control thymoma or thymic carcinoma in people whose cancer progressed after first-line chemotherapy (with or without immunotherapy).

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06838910

• Combining glucocorticoids with chemoradiotherapy for thymoma treatment

  This study is testing if adding a steroid called methylprednisolone to standard chemotherapy and radiation can help people with advanced or recurring thymoma have better treatment results.

  Recruiting Phase 2 Sun Yat-sen University · Guanzhou, Guangdong · NCT06730308

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.